Afatinib almost doubled progression-free survival versus chemotherapy in advanced lung cancer with uncommon EGFR mutations. The treatment effect was consistent across major uncommon mutations, ...

The study offers guidance to clinicians treating the roughly 10% of patients with rare EGFR mutations. Patients with non–small cell lung cancer (NSCLC) who have uncommon EGFR mutations appear to have ...

Please provide your email address to receive an email when new articles are posted on . First-line treatment with afatinib significantly prolonged time-to-treatment failure compared with gefitinib for ...

Afatinib significantly improves progression-free survival among patients with advanced lung cancer that harbors certain genetic mutations compared with standard chemotherapy. Results from a phase 3 ...

Please provide your email address to receive an email when new articles are posted on . Patients with advanced non–small cell lung cancer who harbored EGFR exon 19 deletions and who received ...

LUX-Lung 3 results highlighted at the official ASCO Press Conference: Afatinib* delays cancer progression significantly more than the best standard chemotherapy Ingelheim, Germany, 4 June 2012 –The ...

In advanced non-small cell lung cancer, the new tyrosine-kinase inhibitor is more effective than combination chemotherapy in patients with certain mutations. Evaluable data were only available for non ...

Afatinib (trade name: Giotrif) has been approved since April 2016 for the treatment of adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) of squamous histology who have ...

MADRID — The oral tyrosine kinase inhibitor afatinib (Gilotrif, Boehringer Ingelheim) has shown a modest benefit in patients with recurrent and metastatic head and neck cancer in a phase 3 trial ...

Aims: The aim of this article was to evaluate afatinib (BIBW 2992), an ErbB family blocker, and nintedanib (BIBF 1120), a triple angiokinase inhibitor, in castration-resistant prostate cancer patients ...

Development and Validation of a Radiomics Nomogram for Preoperative Prediction of Lymph Node Metastasis in Colorectal Cancer Between November 2013 and May 2015, adults with a histologic diagnosis of ...

Afatinib (trade name: Giotrif) has been approved since April 2016 for the treatment of adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) of squamous histology who have ...